In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Call the Plumber: PIPE Logic is Leaky

Executive Summary

Extraordinary times for capital markets have made cheap public biotechs attractive to venture investors. These private investments in public equity (PIPEs) are seen by some as a lifeline to a troubled and undervalued sector, and many VCs are considering significant public investments. But few deals are likely to get done as venture funds set a high bar for investment, regardless of fire-sale prices. Recipients of large PIPE deals may indeed provide venture-like returns for private investors, but an analysis of these financings shows why they are the exceptions that prove the rule.
Advertisement

Related Content

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2009
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2009
MedImmune Returns BiTE Compound To Micromet With An Option To Jump Back In
Reacting to the Crisis: Biotech Venture Capital's Plan B
Royalty Flush: Why Monetizing Tomorrow's Revenue Stream Today Could Catch on in a Big Way
Royalty Flush: Why Monetizing Tomorrow's Revenue Stream Today Could Catch on in a Big Way
Phase III Prostate Cancer Failures: Taxotere to Blame?
Phase III Prostate Cancer Failures: Taxotere to Blame?
Securing PIPEs to Progress Fledgling Clinical Portfolios
Securing PIPEs to Progress Fledgling Clinical Portfolios

Topics

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003284

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel